Table 2. Preclinical trials carried out with MSCs in canine ST.

No of dogs	MSC source	Treatment	Observation period	Outcome	Reference
55	AT	1 ml of intratendinous autologous PRP/ASC per tendon (containing 5 × 106 ASCs).	90 days	88% of 25 cases monitored at 90 days, showed no significant difference of the injured limb compared to the contralateral limb.	Canapp et al., 2016a
41	Bone marrow	Intratendinous autologous BMSC and PRP.	90 days	Improvement in the fiber pattern and echogenicity in 90.6% of cases.	McDougall et al., 2018

PRP = Platelet-rich plasma; ASC = Adipose-derived mesenchymal stem cells; BMSC = Bone marrow-derived mesenchymal stem cells.